Prostate Cancer International is
for 2011 by Great NonProfits
Ketoconazole has long been used as a “third-line” agent in men with castration-resistant prostate cancer (CRPC) who have progressive disease after standard forms of hormonal therapy. For some patients, ketoconazole can be clinically effective and cost-effective compared to other clinical options.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acid, acid-suppressive, castration-resistant, CRPC, ketoconazole, suppression | 5 Comments »
An announcement yesterday has made it clear that sunitinib malate (Sutent) is unlikely to ever show significant clinical activity in the management of patients with advanced, castration-resistant prostate cancer (CRPC) after initial chemotherapy.
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, sunitinib | Leave a Comment »
On his Advanced Prostate Cancer blog site, Joel Nowak has just published a series of five brief articles on the opportunities offered by some older agents that are available for use as second-line therapies in the management of patients who have a rising PSA after treatment with standard forms of androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: advanced, castration-resistant, CRPC, estradiol, GM-CSF, ketoconazole, octreotide | 3 Comments »
Data from a French firm called Hybrigenics suggest that a new product, inecalcitol, that targets the vitamin D receptor may have clinical activity in combination with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, inecalcitol | 2 Comments »
Back in 2009 we reported the results of a randomized Phase II trial of docetaxel + OGX-011 vs. docetaxel + placebo as they were initially presented at the annual meeting of the American Society of Clinical Oncology in Chicago (ASCO).
Filed under: Drugs in development | Tagged: CRPC, custirsen, OGX-011 | Leave a Comment »
Bafetinib (previously known as INNO-406) is a protein kinase inhibitor that targets two different enzymes. The newly announced trial is designed to investigate the potential of bafetinib in the treatment of men with castration-resistant prostate cancer (CRPC) who have progressive disease after treatment with at least one course of chemotherapy.
Filed under: Drugs in development | Tagged: bafetinib, castration-resistant, CRPC | Leave a Comment »
Figitumumab (also known as CP-751,871) is a fully humanized monoclonal antibody designed to target the insulin-like growth factor type 1 receptor (IGF-IR). Data are now available from a very early-stage trial of figitumumab in combination with docetaxel in the treatment of patients with late-stage solid tumors — including castration-resiatant prostate cancer (CRPC).
Filed under: Drugs in development | Tagged: 871, castration-resistant prostate cancer, CP-751, CRPC, figitumumab | Leave a Comment »
Traditional forms of hormone therapy for prostate cancer are based on the idea that you reduce testosterone levels as low as you can so as to stop the ability of testosterone and its metabolites (e.g., dihydrotestosterone) to stimulate growth of prostatic tissues — including prostate cancer cells.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, bipolar, castration-resistant, CRPC, therapy | 1 Comment »
In the late 1980s and early 1990s it was generally considered that men diagnosed with metastatic (but still hormone sensitive) prostate cancer had an estimated survival of 18 to 36 months from the time of diagnosis — including their time on treatment with hormonal therapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CRPC, hormone therapy, mCRPC, survival | 6 Comments »
One of the really “hot” pieces of news from ASCO today was the result of a Phase III clinical trial of ipilimumab in a form of metastatic skin cancer called melanoma. This is (perhaps) very important for prostate cancer patients.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, ipilimumab | Leave a Comment »
A new report has suggested that, for men treated with intermittent androgen deprivation therapy (ADT) after biochemical relapse following surgery or radiation, the length of the first time-period off androgen deprivation therapy (ADT) may correlate with time to onset of castration-resistant prostate cancer (CRPC) and prostate cancer-specific mortality.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, castrration-resistant, CRPC, intermittent, survival | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site